Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,610 | -8,943 | -50,636 | -41,502 | -24,697 |
| Depreciation Amortization | 160 | 82 | 312 | 226 | 139 |
| Accounts payable and accrued liabilities | -1,235 | 657 | -974 | -877 | -1,466 |
| Other Working Capital | -864 | -302 | 2,732 | 3,097 | 35 |
| Other Operating Activity | 4,530 | 973 | 6,461 | 4,869 | 4,001 |
| Operating Cash Flow | $-15,019 | $-7,533 | $-42,105 | $-34,187 | $-21,988 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -35,242 | N/A | 24,502 | 18,003 | 24,501 |
| PPE Investments | -100 | N/A | -333 | -324 | -31 |
| Investing Cash Flow | $-35,342 | $N/A | $24,169 | $17,679 | $24,470 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 19,885 | 19,885 | N/A |
| Financing Cash Flow | $N/A | $N/A | $19,885 | $19,885 | $N/A |
| Beginning Cash Position | 71,436 | 71,436 | 69,487 | 69,487 | 69,487 |
| End Cash Position | 21,075 | 63,903 | 71,436 | 72,864 | 71,969 |
| Net Cash Flow | $-50,361 | $-7,533 | $1,949 | $3,377 | $2,482 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,019 | -7,533 | -42,105 | -34,187 | -21,988 |
| Capital Expenditure | -100 | N/A | -333 | -324 | -31 |
| Free Cash Flow | -15,119 | -7,533 | -42,438 | -34,511 | -22,019 |